Skip to main content
Erschienen in: Current Cardiovascular Risk Reports 2/2010

01.03.2010

Inflammation: The Link Between Obesity and Cardiovascular Risk

verfasst von: Paolo Calabrò, Enrica Golia, Lucia Riegler, Giuseppe Limongelli, Paolo Golino, Maria Giovanna Russo, Raffaele Calabrò

Erschienen in: Current Cardiovascular Risk Reports | Ausgabe 2/2010

Einloggen, um Zugang zu erhalten

Abstract

It is now clear that adipose tissue is more than just an area for fat storage, as suggested by a large body of recent literature. Fat, in particular abdominal depots, is an active source of biological mediators, which affect metabolic pathways and vascular function. These effects seem to be in part related to inflammation, especially in the pathogenesis and progression of atherosclerosis. As cardiovascular pathology, in particular coronary artery disease, still represents one of the main causes of morbidity and mortality in Western countries, the need for markers to make a correct risk stratification of patients is rising with the increasing complexity of treatment strategies now available. Thus, molecules produced by adipose tissue, known as adipocytokines, have been studied largely for their potential use as biomarkers both in primary and secondary prevention. The aim of this article is to examine recent evidence about the main adipocytokines, including leptin, adiponectin, resistin, and C-reactive protein, of which adipose tissue an important source.
Literatur
1.
Zurück zum Zitat Grundy SM: Obesity, metabolic syndrome, and coronary atherosclerosis. Circulation 2002, 105:2696–2698.CrossRefPubMed Grundy SM: Obesity, metabolic syndrome, and coronary atherosclerosis. Circulation 2002, 105:2696–2698.CrossRefPubMed
2.
Zurück zum Zitat Vague J: The degree of masculine differentiation of obesities: a factor determining predisposition to diabetes, atherosclerosis, gout, and uric calculous disease. Am J Clin Nutr 1956, 4:20–34.PubMed Vague J: The degree of masculine differentiation of obesities: a factor determining predisposition to diabetes, atherosclerosis, gout, and uric calculous disease. Am J Clin Nutr 1956, 4:20–34.PubMed
3.
Zurück zum Zitat Calabrò P, Limongelli G, Pacileo G, et al.: The role of adiposity as a determinant of an inflammatory milieu. J Cardiovasc Med (Hagerstown) 2008, 9:450–460. Calabrò P, Limongelli G, Pacileo G, et al.: The role of adiposity as a determinant of an inflammatory milieu. J Cardiovasc Med (Hagerstown) 2008, 9:450–460.
4.
Zurück zum Zitat Skurk T, Alberti-Huber C, Herder C, Hauner H: Relationship between adipocyte size and adipokine expression and secretion. J Clin Endocrinol Metab 2007, 92:1023–1033.CrossRefPubMed Skurk T, Alberti-Huber C, Herder C, Hauner H: Relationship between adipocyte size and adipokine expression and secretion. J Clin Endocrinol Metab 2007, 92:1023–1033.CrossRefPubMed
5.
Zurück zum Zitat • Calabrò P, Golia E, Maddaloni V, et al.: Adipose tissue-mediated inflammation: the missing link between obesity and cardiovascular disease? Intern Emerg Med 2009, 4:25–34. This is recent review on the molecular mechanisms linking adipose tissue, inflammation, and cardiovascular diseases.CrossRefPubMed • Calabrò P, Golia E, Maddaloni V, et al.: Adipose tissue-mediated inflammation: the missing link between obesity and cardiovascular disease? Intern Emerg Med 2009, 4:25–34. This is recent review on the molecular mechanisms linking adipose tissue, inflammation, and cardiovascular diseases.CrossRefPubMed
6.
Zurück zum Zitat Weisberg SP, McCann D, Desai M, et al.: Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003, 112:1796–1808.PubMed Weisberg SP, McCann D, Desai M, et al.: Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003, 112:1796–1808.PubMed
7.
Zurück zum Zitat Calabro P, Chang DW, Willerson JT, Yeh ET: Release of C-reactive protein in response to inflammatory cytokines by human adipocytes: linking obesity to vascular inflammation. J Am Coll Cardiol 2005, 46:1112–1113.CrossRefPubMed Calabro P, Chang DW, Willerson JT, Yeh ET: Release of C-reactive protein in response to inflammatory cytokines by human adipocytes: linking obesity to vascular inflammation. J Am Coll Cardiol 2005, 46:1112–1113.CrossRefPubMed
8.
Zurück zum Zitat Calabro P, Chang DW, Willerson JT, Yeh ET: Production of C-reactive protein and serum amyloid A in response to inflammatory cytokines by human adipocytes. Eur Heart J 2005, 26:334–335. Calabro P, Chang DW, Willerson JT, Yeh ET: Production of C-reactive protein and serum amyloid A in response to inflammatory cytokines by human adipocytes. Eur Heart J 2005, 26:334–335.
9.
Zurück zum Zitat Cousin B, Munoz O, Andre M, et al.: A role for preadipocytes as macrophage-like cells. FASEB J 1999, 13:305–312.PubMed Cousin B, Munoz O, Andre M, et al.: A role for preadipocytes as macrophage-like cells. FASEB J 1999, 13:305–312.PubMed
10.
Zurück zum Zitat Braunwald E: Shattuck lecture—cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. N Engl J Med 1997, 337:1360–1369.CrossRefPubMed Braunwald E: Shattuck lecture—cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. N Engl J Med 1997, 337:1360–1369.CrossRefPubMed
11.
Zurück zum Zitat Khot UN, Khot MB, Bajzer CT, et al.: Prevalence of conventional risk factors in patients with coronary heart disease. JAMA 2003, 290:898–904.CrossRefPubMed Khot UN, Khot MB, Bajzer CT, et al.: Prevalence of conventional risk factors in patients with coronary heart disease. JAMA 2003, 290:898–904.CrossRefPubMed
12.
Zurück zum Zitat Greenland P, Knoll MD, Stamler J, et al.: Major risk factors as antecedents of fatal and nonfatal coronary heart disease events. JAMA 2003, 290:891–897.CrossRefPubMed Greenland P, Knoll MD, Stamler J, et al.: Major risk factors as antecedents of fatal and nonfatal coronary heart disease events. JAMA 2003, 290:891–897.CrossRefPubMed
13.
Zurück zum Zitat Canto JG, Iskandrian AE: Major risk factors for cardiovascular disease: debunking the “only 50%” myth. JAMA 2003, 290:947.CrossRefPubMed Canto JG, Iskandrian AE: Major risk factors for cardiovascular disease: debunking the “only 50%” myth. JAMA 2003, 290:947.CrossRefPubMed
14.
Zurück zum Zitat Chu NF, Spiegelman D, Hotamisligil GS, et al.: Plasma insulin, leptin, and soluble TNF receptors levels in relation to obesity-related atherogenic and thrombogenic cardiovascular disease risk factors among men. Atherosclerosis 2001, 157:495–503.CrossRefPubMed Chu NF, Spiegelman D, Hotamisligil GS, et al.: Plasma insulin, leptin, and soluble TNF receptors levels in relation to obesity-related atherogenic and thrombogenic cardiovascular disease risk factors among men. Atherosclerosis 2001, 157:495–503.CrossRefPubMed
15.
Zurück zum Zitat Donahue RP, Prineas RJ, Donahue RD, et al.: Is fasting leptin associated with insulin resistance among nondiabetic individuals? The Miami Community Health Study. Diabetes Care 1999, 22:1092–1096.CrossRefPubMed Donahue RP, Prineas RJ, Donahue RD, et al.: Is fasting leptin associated with insulin resistance among nondiabetic individuals? The Miami Community Health Study. Diabetes Care 1999, 22:1092–1096.CrossRefPubMed
16.
Zurück zum Zitat Leyva F, Godsland IF, Ghatei M, et al.: Hyperleptinemia as a component of a metabolic syndrome of cardiovascular risk. Arterioscler Thromb Vasc Biol 1998, 18:928–933.PubMed Leyva F, Godsland IF, Ghatei M, et al.: Hyperleptinemia as a component of a metabolic syndrome of cardiovascular risk. Arterioscler Thromb Vasc Biol 1998, 18:928–933.PubMed
17.
Zurück zum Zitat Zimmet PZ, Collins VR, de Courten MP, et al., on behalf of Mauritius NCD Study Group: Is there a relationship between leptin and insulin sensitivity independent of obesity? A population-based study in the Indian Ocean nation of Mauritius. Int J Obes Relat Metab Disord 1998, 22:171–177.CrossRefPubMed Zimmet PZ, Collins VR, de Courten MP, et al., on behalf of Mauritius NCD Study Group: Is there a relationship between leptin and insulin sensitivity independent of obesity? A population-based study in the Indian Ocean nation of Mauritius. Int J Obes Relat Metab Disord 1998, 22:171–177.CrossRefPubMed
18.
Zurück zum Zitat Soderberg S, Ahren B, Jansson JH, et al.: Leptin is associated with increased risk of myocardial infarction. J Intern Med 1999, 246:409–418.CrossRefPubMed Soderberg S, Ahren B, Jansson JH, et al.: Leptin is associated with increased risk of myocardial infarction. J Intern Med 1999, 246:409–418.CrossRefPubMed
19.
Zurück zum Zitat Wallace AM, McMahon AD, Packard CJ, et al.: Plasma leptin and the risk of cardiovascular disease in the West Of Scotland Coronary Prevention Study (WOSCOPS). Circulation 2001, 104:3052–3056.CrossRefPubMed Wallace AM, McMahon AD, Packard CJ, et al.: Plasma leptin and the risk of cardiovascular disease in the West Of Scotland Coronary Prevention Study (WOSCOPS). Circulation 2001, 104:3052–3056.CrossRefPubMed
20.
Zurück zum Zitat Wolk R, Berger P, Lennon RJ, et al.: Plasma leptin and prognosis in patients with established coronary atherosclerosis. J Am Coll Cardiol 2004, 44:1819–1824.CrossRefPubMed Wolk R, Berger P, Lennon RJ, et al.: Plasma leptin and prognosis in patients with established coronary atherosclerosis. J Am Coll Cardiol 2004, 44:1819–1824.CrossRefPubMed
21.
Zurück zum Zitat Lawlor DA, Davey Smith G, Kelly A, et al.: Leptin and coronary heart disease risk: prospective case control study of British women. Obesity (Silver Spring) 2007, 15:1694–1701.CrossRef Lawlor DA, Davey Smith G, Kelly A, et al.: Leptin and coronary heart disease risk: prospective case control study of British women. Obesity (Silver Spring) 2007, 15:1694–1701.CrossRef
22.
Zurück zum Zitat Sattar N, Wannamethee G, Sarwar N, et al.: Leptin and coronary heart disease: prospective study and systematic review. J Am Coll Cardiol 2009, 53:167–175.CrossRefPubMed Sattar N, Wannamethee G, Sarwar N, et al.: Leptin and coronary heart disease: prospective study and systematic review. J Am Coll Cardiol 2009, 53:167–175.CrossRefPubMed
23.
Zurück zum Zitat Amasyali B, Aytemir K, Kose S, et al.: Admission plasma leptin level strongly correlates with the success of thrombolytic therapy in patients with acute myocardial infarction. Angiology 2006 57:671–680.CrossRefPubMed Amasyali B, Aytemir K, Kose S, et al.: Admission plasma leptin level strongly correlates with the success of thrombolytic therapy in patients with acute myocardial infarction. Angiology 2006 57:671–680.CrossRefPubMed
24.
Zurück zum Zitat Söderberg S, Colquhoun D, Keech A, et al.; LIPID Study Investigators: Leptin, but not adiponectin, is a predictor of recurrent cardiovascular events in men: results from the LIPID study. Int J Obes (Lond) 2009, 33:123–130.CrossRef Söderberg S, Colquhoun D, Keech A, et al.; LIPID Study Investigators: Leptin, but not adiponectin, is a predictor of recurrent cardiovascular events in men: results from the LIPID study. Int J Obes (Lond) 2009, 33:123–130.CrossRef
25.
Zurück zum Zitat Karakas M, Zierer A, Herder C, et al.: Leptin, adiponectin, their ratio and risk of coronary heart disease: results from the MONICA/KORA Augsburg Study 1984–2002. Atherosclerosis 2009 Aug 20 [epub ahead of print]. Karakas M, Zierer A, Herder C, et al.: Leptin, adiponectin, their ratio and risk of coronary heart disease: results from the MONICA/KORA Augsburg Study 1984–2002. Atherosclerosis 2009 Aug 20 [epub ahead of print].
26.
Zurück zum Zitat Sharma AM: Adipose tissue: a mediator of cardiovascular risk. Int J Obes Relat Metab Disord 2002, 26(Suppl 4):S5–S7.CrossRefPubMed Sharma AM: Adipose tissue: a mediator of cardiovascular risk. Int J Obes Relat Metab Disord 2002, 26(Suppl 4):S5–S7.CrossRefPubMed
27.
Zurück zum Zitat Ouchi N, Kihara S, Arita Y, et al.: Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 1999, 100:2473–2476.PubMed Ouchi N, Kihara S, Arita Y, et al.: Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 1999, 100:2473–2476.PubMed
28.
Zurück zum Zitat Pischon T, Girman CJ, Hotamisligil GS, et al.: Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 2004, 291:1730–1737.CrossRefPubMed Pischon T, Girman CJ, Hotamisligil GS, et al.: Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 2004, 291:1730–1737.CrossRefPubMed
29.
Zurück zum Zitat Maahs DM, Ogden LG, Kinney GL, et al.: Low plasma adiponectin levels predict progression of coronary artery calcification. Circulation 2005, 111:747–753.CrossRefPubMed Maahs DM, Ogden LG, Kinney GL, et al.: Low plasma adiponectin levels predict progression of coronary artery calcification. Circulation 2005, 111:747–753.CrossRefPubMed
30.
Zurück zum Zitat Wolk R, Berger P, Lennon RJ, et al.: Association between plasma adiponectin levels and unstable coronary syndromes. Eur Heart J 2007, 28:292–298.CrossRefPubMed Wolk R, Berger P, Lennon RJ, et al.: Association between plasma adiponectin levels and unstable coronary syndromes. Eur Heart J 2007, 28:292–298.CrossRefPubMed
31.
Zurück zum Zitat Liang KW, Sheu WH, Lee WL, et al.: Decreased circulating protective adiponectin level is associated with angiographic coronary disease progression in patients with angina pectoris. Int J Cardiol 2008, 129:76–80.CrossRefPubMed Liang KW, Sheu WH, Lee WL, et al.: Decreased circulating protective adiponectin level is associated with angiographic coronary disease progression in patients with angina pectoris. Int J Cardiol 2008, 129:76–80.CrossRefPubMed
32.
Zurück zum Zitat Sattar N, Wannamethee G, Sarwar N, et al.: Adiponectin and coronary heart disease: a prospective study and meta-analysis. Circulation 2006, 114:623–629. (Published erratum appears in Circulation 2007, 115:e325.)CrossRefPubMed Sattar N, Wannamethee G, Sarwar N, et al.: Adiponectin and coronary heart disease: a prospective study and meta-analysis. Circulation 2006, 114:623–629. (Published erratum appears in Circulation 2007, 115:e325.)CrossRefPubMed
33.
Zurück zum Zitat Lawlor DA, Davey Smith G, Ebrahim S, et al.: Plasma adiponectin levels are associated with insulin resistance, but do not predict future risk of coronary heart disease in women. J Clin Endocrinol Metab 2005, 90:5677–5683.CrossRefPubMed Lawlor DA, Davey Smith G, Ebrahim S, et al.: Plasma adiponectin levels are associated with insulin resistance, but do not predict future risk of coronary heart disease in women. J Clin Endocrinol Metab 2005, 90:5677–5683.CrossRefPubMed
34.
Zurück zum Zitat Antoniades C, Antonopoulos AS, Tousoulis D, Stefanadis C: Adiponectin: from obesity to cardiovascular disease. Obes Rev 2009, 10:269–279.CrossRefPubMed Antoniades C, Antonopoulos AS, Tousoulis D, Stefanadis C: Adiponectin: from obesity to cardiovascular disease. Obes Rev 2009, 10:269–279.CrossRefPubMed
35.
Zurück zum Zitat Zhang MH, Spies C, Ali S, et al.: Adiponectin and inducible ischemia in patients with stable coronary heart disease: data from the Heart and Soul study. Atherosclerosis. 2009, 205:233–238.CrossRefPubMed Zhang MH, Spies C, Ali S, et al.: Adiponectin and inducible ischemia in patients with stable coronary heart disease: data from the Heart and Soul study. Atherosclerosis. 2009, 205:233–238.CrossRefPubMed
36.
Zurück zum Zitat Rathmann W, Haastert B, Herder C, et al.: Differential association of adiponectin with cardiovascular risk markers in men and women? The KORA survey 2000. Int J Obes (Lond) 2007, 31:770–776. Rathmann W, Haastert B, Herder C, et al.: Differential association of adiponectin with cardiovascular risk markers in men and women? The KORA survey 2000. Int J Obes (Lond) 2007, 31:770–776.
37.
Zurück zum Zitat Degawa-Yamauchi M, Bovenkerk JE, Juliar BE, et al.: Serum resistin (FIZZ3) protein is increased in obese humans. J Clin Endocrinol Metab 2003, 88:5452–5455.CrossRefPubMed Degawa-Yamauchi M, Bovenkerk JE, Juliar BE, et al.: Serum resistin (FIZZ3) protein is increased in obese humans. J Clin Endocrinol Metab 2003, 88:5452–5455.CrossRefPubMed
38.
Zurück zum Zitat Azuma K, Katsukawa F, Oguchi S, et al.: Correlation between serum resistin level and adiposity in obese individuals. Obes Res 2003, 11:997–1001.CrossRefPubMed Azuma K, Katsukawa F, Oguchi S, et al.: Correlation between serum resistin level and adiposity in obese individuals. Obes Res 2003, 11:997–1001.CrossRefPubMed
39.
Zurück zum Zitat Lee JH, Chan JL, Yiannakouris N, et al.: Circulating resistin levels are not associated with obesity or insulin resistance in humans and are not regulated by fasting or leptin administration: cross-sectional and interventional studies in normal, insulin-resistant, and diabetic subjects. J Clin Endocrinol Metab 2003, 88:4848–4856.CrossRefPubMed Lee JH, Chan JL, Yiannakouris N, et al.: Circulating resistin levels are not associated with obesity or insulin resistance in humans and are not regulated by fasting or leptin administration: cross-sectional and interventional studies in normal, insulin-resistant, and diabetic subjects. J Clin Endocrinol Metab 2003, 88:4848–4856.CrossRefPubMed
40.
Zurück zum Zitat Utzschneider KM, Carr DB, Tong J, et al.: Resistin is not associated with insulin sensitivity or the metabolic syndrome in humans. Diabetologia 2005, 48:2330–2333.CrossRefPubMed Utzschneider KM, Carr DB, Tong J, et al.: Resistin is not associated with insulin sensitivity or the metabolic syndrome in humans. Diabetologia 2005, 48:2330–2333.CrossRefPubMed
41.
Zurück zum Zitat Gomez-Ambrosi J, Fruhbeck G: Do resistin and resistin-like molecules also link obesity to inflammatory diseases? Ann Intern Med 2001, 135:306–307.PubMed Gomez-Ambrosi J, Fruhbeck G: Do resistin and resistin-like molecules also link obesity to inflammatory diseases? Ann Intern Med 2001, 135:306–307.PubMed
42.
Zurück zum Zitat Ohmori R, Momiyama Y, Kato R, et al.: Associations between serum resistin levels and insulin resistance, inflammation, and coronary artery disease. J Am Coll Cardiol 2005, 46:379–380.CrossRefPubMed Ohmori R, Momiyama Y, Kato R, et al.: Associations between serum resistin levels and insulin resistance, inflammation, and coronary artery disease. J Am Coll Cardiol 2005, 46:379–380.CrossRefPubMed
43.
Zurück zum Zitat Reilly MP, Lehrke M, Wolfe ML, et al.: Resistin is an inflammatory marker of atherosclerosis in humans. Circulation 2005, 111:932–939.CrossRefPubMed Reilly MP, Lehrke M, Wolfe ML, et al.: Resistin is an inflammatory marker of atherosclerosis in humans. Circulation 2005, 111:932–939.CrossRefPubMed
44.
Zurück zum Zitat Pischon T, Bamberger CM, Kratzsch J, et al.: Association of plasma resistin levels with coronary heart disease in women. Obes Res 2005, 13:1764–1771.CrossRefPubMed Pischon T, Bamberger CM, Kratzsch J, et al.: Association of plasma resistin levels with coronary heart disease in women. Obes Res 2005, 13:1764–1771.CrossRefPubMed
45.
Zurück zum Zitat Pilz S, Weihrauch G, Seelhorst U, et al.: Implications of resistin plasma levels in subjects undergoing coronary angiography. Clin Endocrinol (Oxford) 2007, 66:380–386.CrossRef Pilz S, Weihrauch G, Seelhorst U, et al.: Implications of resistin plasma levels in subjects undergoing coronary angiography. Clin Endocrinol (Oxford) 2007, 66:380–386.CrossRef
46.
Zurück zum Zitat Lubos E, Messow CM, Schnabel R, et al.: Resistin, acute coronary syndrome and prognosis results from the AtheroGene study. Atherosclerosis 2007, 193:121–128.CrossRefPubMed Lubos E, Messow CM, Schnabel R, et al.: Resistin, acute coronary syndrome and prognosis results from the AtheroGene study. Atherosclerosis 2007, 193:121–128.CrossRefPubMed
47.
Zurück zum Zitat Diez JJ, Iglesias P, Fernandez-Reyes MJ, et al.: Serum concentrations of leptin, adiponectin and resistin, and their relationship with cardiovascular disease in patients with end-stage renal disease. Clin Endocrinol (Oxford) 2005, 62:242–249.CrossRef Diez JJ, Iglesias P, Fernandez-Reyes MJ, et al.: Serum concentrations of leptin, adiponectin and resistin, and their relationship with cardiovascular disease in patients with end-stage renal disease. Clin Endocrinol (Oxford) 2005, 62:242–249.CrossRef
48.
Zurück zum Zitat Weikert C, Westphal S, Berger K, et al.: Plasma resistin levels and risk of myocardial infarction and ischemic stroke. Clin Endocrinol Metab 2008, 93:2647–2653.CrossRef Weikert C, Westphal S, Berger K, et al.: Plasma resistin levels and risk of myocardial infarction and ischemic stroke. Clin Endocrinol Metab 2008, 93:2647–2653.CrossRef
49.
Zurück zum Zitat • Calabrò P, Golia E, Yeh ET: CRP and the risk of atherosclerotic events. Semin Immunopathol 2009, 31:79–94. This is a recent review on CRP and the risk of cardiovascular events, both on the molecular and clinical level.CrossRefPubMed • Calabrò P, Golia E, Yeh ET: CRP and the risk of atherosclerotic events. Semin Immunopathol 2009, 31:79–94. This is a recent review on CRP and the risk of cardiovascular events, both on the molecular and clinical level.CrossRefPubMed
50.
Zurück zum Zitat Memoli B, Procino A, Calabrò P, et al.: Inflammation may modulate interleukin 6 and C-reactive protein gene expression in the adipose tissue: the role of IL-6 cell membrane receptor. Am J Physiol Endocrinol Metab 2007, 293:E1030–E1035.CrossRefPubMed Memoli B, Procino A, Calabrò P, et al.: Inflammation may modulate interleukin 6 and C-reactive protein gene expression in the adipose tissue: the role of IL-6 cell membrane receptor. Am J Physiol Endocrinol Metab 2007, 293:E1030–E1035.CrossRefPubMed
51.
Zurück zum Zitat Ouchi N, Kihara S, Funahashi T, et al.: Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation 2003, 107:671–674.CrossRefPubMed Ouchi N, Kihara S, Funahashi T, et al.: Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation 2003, 107:671–674.CrossRefPubMed
52.
Zurück zum Zitat Anty R, Bekri S, Luciani N, et al.: The inflammatory C-reactive protein is increased in both liver and adipose tissue in severely obese patients independently from metabolic syndrome, type 2 diabetes, and NASH. Am J Gastroenterol 2006, 101:1824–1833.CrossRefPubMed Anty R, Bekri S, Luciani N, et al.: The inflammatory C-reactive protein is increased in both liver and adipose tissue in severely obese patients independently from metabolic syndrome, type 2 diabetes, and NASH. Am J Gastroenterol 2006, 101:1824–1833.CrossRefPubMed
53.
Zurück zum Zitat Ridker PM, Cushman M, Stampfer MJ, et al.: Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997, 336:973–979. (Published erratum appears in N Engl J Med 1997, 337:356.)CrossRefPubMed Ridker PM, Cushman M, Stampfer MJ, et al.: Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997, 336:973–979. (Published erratum appears in N Engl J Med 1997, 337:356.)CrossRefPubMed
54.
Zurück zum Zitat • Ridker PM, Buring JE, Rifai N, Cook NR: Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds risk score. JAMA 2007, 297:611–619. (Published erratum appears in JAMA 2007, 297:1433). This article proposed a novel algorithm for the assessment of cardiovascular risk, including inflammation as reflected by CRP levels.CrossRefPubMed • Ridker PM, Buring JE, Rifai N, Cook NR: Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds risk score. JAMA 2007, 297:611–619. (Published erratum appears in JAMA 2007, 297:1433). This article proposed a novel algorithm for the assessment of cardiovascular risk, including inflammation as reflected by CRP levels.CrossRefPubMed
55.
Zurück zum Zitat Ridker PM, Paynter NP, Rifai N, et al.: C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men. Circulation 2008, 118:2243–2251.CrossRefPubMed Ridker PM, Paynter NP, Rifai N, et al.: C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men. Circulation 2008, 118:2243–2251.CrossRefPubMed
56.
Zurück zum Zitat Pearson TA, Mensah GA, Alexander RW, et al.: Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003, 107:499–511.CrossRefPubMed Pearson TA, Mensah GA, Alexander RW, et al.: Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003, 107:499–511.CrossRefPubMed
57.
Zurück zum Zitat Ridker PM, Danielson E, Fonseca FA, et al.; JUPITER Study Group: Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008, 359:2195–2207.CrossRefPubMed Ridker PM, Danielson E, Fonseca FA, et al.; JUPITER Study Group: Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008, 359:2195–2207.CrossRefPubMed
58.
Zurück zum Zitat Sinning JM, Bickel C, Messow CM, et al.: Impact of C-reactive protein and fibrinogen on cardiovascular prognosis in patients with stable angina pectoris: the AtheroGene study. Eur Heart J 2006, 27:2962–2968.CrossRefPubMed Sinning JM, Bickel C, Messow CM, et al.: Impact of C-reactive protein and fibrinogen on cardiovascular prognosis in patients with stable angina pectoris: the AtheroGene study. Eur Heart J 2006, 27:2962–2968.CrossRefPubMed
59.
Zurück zum Zitat Arroyo-Espliguero R, Avanzas P, Quiles J, Kaski JC: Predictive value of coronary artery stenoses and C-reactive protein levels in patients with stable coronary artery disease. Atherosclerosis 2009, 204:239–243.CrossRefPubMed Arroyo-Espliguero R, Avanzas P, Quiles J, Kaski JC: Predictive value of coronary artery stenoses and C-reactive protein levels in patients with stable coronary artery disease. Atherosclerosis 2009, 204:239–243.CrossRefPubMed
60.
Zurück zum Zitat Hoffmann R, Suliman H, Haager P, et al.: Association of C-reactive protein and myocardial perfusion in patients with ST elevation acute myocardial infarction. Atherosclerosis 2006, 186:177–183.CrossRefPubMed Hoffmann R, Suliman H, Haager P, et al.: Association of C-reactive protein and myocardial perfusion in patients with ST elevation acute myocardial infarction. Atherosclerosis 2006, 186:177–183.CrossRefPubMed
61.
Zurück zum Zitat Nakachi T, Kosuge M, Hibi K, et al.: C-reactive protein elevation and rapid angiographic progression of nonculprit lesion in patients with non-ST-segment elevation acute coronary syndrome. Circ J 2008, 72:1953–1959.CrossRefPubMed Nakachi T, Kosuge M, Hibi K, et al.: C-reactive protein elevation and rapid angiographic progression of nonculprit lesion in patients with non-ST-segment elevation acute coronary syndrome. Circ J 2008, 72:1953–1959.CrossRefPubMed
62.
Zurück zum Zitat Bogaty P, Boyer L, Simard S, et al.: Clinical utility of C-reactive protein measured at admission, hospital discharge, and 1 month later to predict outcome in patients with acute coronary disease. The RISCA (Recurrence and Inflammation in Acute Coronary Syndromes) study. J Am Coll Cardiol 2008, 51:2339–2346.CrossRefPubMed Bogaty P, Boyer L, Simard S, et al.: Clinical utility of C-reactive protein measured at admission, hospital discharge, and 1 month later to predict outcome in patients with acute coronary disease. The RISCA (Recurrence and Inflammation in Acute Coronary Syndromes) study. J Am Coll Cardiol 2008, 51:2339–2346.CrossRefPubMed
63.
64.
Zurück zum Zitat Visser M, Bouter LM, McQuillan GM, et al.: Elevated C-reactive protein levels in overweight and obese adults. JAMA 1999, 282:2131–2135.CrossRefPubMed Visser M, Bouter LM, McQuillan GM, et al.: Elevated C-reactive protein levels in overweight and obese adults. JAMA 1999, 282:2131–2135.CrossRefPubMed
65.
Zurück zum Zitat Patel SB, Reams GP, Spear RM, et al.: Leptin: linking obesity, the metabolic syndrome, and cardiovascular disease. Curr Hypertens Rep 2008, 10:131–137.CrossRefPubMed Patel SB, Reams GP, Spear RM, et al.: Leptin: linking obesity, the metabolic syndrome, and cardiovascular disease. Curr Hypertens Rep 2008, 10:131–137.CrossRefPubMed
66.
Zurück zum Zitat Spalding KL, Arner E, Westermark PO, et al.: Dynamics of fat cell turnover in humans. Nature 2008, 453:783–787.CrossRefPubMed Spalding KL, Arner E, Westermark PO, et al.: Dynamics of fat cell turnover in humans. Nature 2008, 453:783–787.CrossRefPubMed
67.
Zurück zum Zitat Goodpaster BH, Kelley DE, Wing RR, et al.: Effects of weight loss on regional fat distribution and insulin sensitivity in obesity. Diabetes 1999, 48:839–847.CrossRefPubMed Goodpaster BH, Kelley DE, Wing RR, et al.: Effects of weight loss on regional fat distribution and insulin sensitivity in obesity. Diabetes 1999, 48:839–847.CrossRefPubMed
68.
Zurück zum Zitat Donnelly JE, Hill JO, Jacobsen DJ, et al.: Effects of a 16-month randomized controlled exercise trial on body weight and composition in young, overweight men and women: the Midwest Exercise Trial. Arch Intern Med 2003, 163:1343–1350.CrossRefPubMed Donnelly JE, Hill JO, Jacobsen DJ, et al.: Effects of a 16-month randomized controlled exercise trial on body weight and composition in young, overweight men and women: the Midwest Exercise Trial. Arch Intern Med 2003, 163:1343–1350.CrossRefPubMed
69.
Zurück zum Zitat Racette SB, Weiss EP, Villareal DT, et al.: One year of caloric restriction in humans: feasibility and effects on body composition and abdominal adipose tissue. J Gerontol Ser A Biol Sci Med Sci 2006, 61:943–950. Racette SB, Weiss EP, Villareal DT, et al.: One year of caloric restriction in humans: feasibility and effects on body composition and abdominal adipose tissue. J Gerontol Ser A Biol Sci Med Sci 2006, 61:943–950.
70.
Zurück zum Zitat Larson-Meyer DE, Heilbronn LK, Redman LM, et al.: Effect of calorie restriction with or without exercise on insulin sensitivity, beta-cell function, fat cell size, and ectopic lipid in overweight subjects. Diabetes Care 2006, 29:1337–1344.CrossRefPubMed Larson-Meyer DE, Heilbronn LK, Redman LM, et al.: Effect of calorie restriction with or without exercise on insulin sensitivity, beta-cell function, fat cell size, and ectopic lipid in overweight subjects. Diabetes Care 2006, 29:1337–1344.CrossRefPubMed
71.
Zurück zum Zitat Varady KA, Tussing L, Bhutani S, Braunschweig CL: Degree of weight loss required to improve adipokine concentrations and decrease fat cell size in severely obese women. Metabolism 2009, 58:1096–1101.CrossRefPubMed Varady KA, Tussing L, Bhutani S, Braunschweig CL: Degree of weight loss required to improve adipokine concentrations and decrease fat cell size in severely obese women. Metabolism 2009, 58:1096–1101.CrossRefPubMed
72.
Zurück zum Zitat Madsen EL, Rissanen A, Bruun JM, et al.: Weight loss larger than 10% is needed for general improvement of levels of circulating adiponectin and markers of inflammation in obese subjects: a 3-year weight loss study. Eur J Endocrinol 2008, 158:179–187.CrossRefPubMed Madsen EL, Rissanen A, Bruun JM, et al.: Weight loss larger than 10% is needed for general improvement of levels of circulating adiponectin and markers of inflammation in obese subjects: a 3-year weight loss study. Eur J Endocrinol 2008, 158:179–187.CrossRefPubMed
73.
Zurück zum Zitat Selvin E, Paynter NP, Erlinger TP: The effect of weight loss on C-reactive protein: a systematic review. Arch Intern Med 2007, 167:31–39.CrossRefPubMed Selvin E, Paynter NP, Erlinger TP: The effect of weight loss on C-reactive protein: a systematic review. Arch Intern Med 2007, 167:31–39.CrossRefPubMed
74.
Zurück zum Zitat Bougoulia M, Triantos A, Koliakos G: Effect of weight loss with or without orlistat treatment on adipocytokines, inflammation, and oxidative markers in obese women. Hormones (Athens). 2006, 5:259–269. Bougoulia M, Triantos A, Koliakos G: Effect of weight loss with or without orlistat treatment on adipocytokines, inflammation, and oxidative markers in obese women. Hormones (Athens). 2006, 5:259–269.
75.
Zurück zum Zitat Heilbronn LK, Noakes M, Clifton PM: Energy restriction and weight loss on very-low-fat diets reduce C-reactive protein concentrations in obese, healthy women. Arterioscler Thromb Vasc Biol 2001, 21:968–970.PubMed Heilbronn LK, Noakes M, Clifton PM: Energy restriction and weight loss on very-low-fat diets reduce C-reactive protein concentrations in obese, healthy women. Arterioscler Thromb Vasc Biol 2001, 21:968–970.PubMed
76.
Zurück zum Zitat O’Brien KD, Brehm BJ, Seeley RJ, et al.: Diet-induced weight loss is associated with decreases in plasma serum amyloid a and C-reactive protein independent of dietary macronutrient composition in obese subjects. J Clin Endocrinol Metab 2005, 90:2244–2249.CrossRefPubMed O’Brien KD, Brehm BJ, Seeley RJ, et al.: Diet-induced weight loss is associated with decreases in plasma serum amyloid a and C-reactive protein independent of dietary macronutrient composition in obese subjects. J Clin Endocrinol Metab 2005, 90:2244–2249.CrossRefPubMed
77.
Zurück zum Zitat You T, Berman DM, Ryan AS, Nicklas BJ: Effects of hypocaloric diet and exercise training on inflammation and adipocyte lipolysis in obese postmenopausal women. J Clin Endocrinol Metab 2004, 89:1739–1746. (Published erratum appears in J Clin Endocrinol Metab 2004, 89:2972.)CrossRefPubMed You T, Berman DM, Ryan AS, Nicklas BJ: Effects of hypocaloric diet and exercise training on inflammation and adipocyte lipolysis in obese postmenopausal women. J Clin Endocrinol Metab 2004, 89:1739–1746. (Published erratum appears in J Clin Endocrinol Metab 2004, 89:2972.)CrossRefPubMed
78.
Zurück zum Zitat Forsythe LK, Wallace JM, Livingstone MB: “Obesity and inflammation: the effects of weight loss.”. Nutr Res Rev 2008, 21:117–133.CrossRefPubMed Forsythe LK, Wallace JM, Livingstone MB: “Obesity and inflammation: the effects of weight loss.”. Nutr Res Rev 2008, 21:117–133.CrossRefPubMed
79.
Zurück zum Zitat Wood RJ, Volek JS, Davis SR, et al.: Effects of a carbohydrate-restricted diet on emerging plasma markers for cardiovascular disease. Nutr Metab (London) 2006, 3:19.CrossRef Wood RJ, Volek JS, Davis SR, et al.: Effects of a carbohydrate-restricted diet on emerging plasma markers for cardiovascular disease. Nutr Metab (London) 2006, 3:19.CrossRef
80.
Zurück zum Zitat Noakes M, Keogh JB, Foster PR, Clifton PM: Effect of an energy-restricted, high-protein, low-fat diet relative to a conventional high-carbohydrate, low-fat diet on weight loss, body composition, nutritional status, and markers of cardiovascular health in obese women. Am J Clin Nutr 2005, 81:1298–1306.PubMed Noakes M, Keogh JB, Foster PR, Clifton PM: Effect of an energy-restricted, high-protein, low-fat diet relative to a conventional high-carbohydrate, low-fat diet on weight loss, body composition, nutritional status, and markers of cardiovascular health in obese women. Am J Clin Nutr 2005, 81:1298–1306.PubMed
81.
Zurück zum Zitat Pereira MA, Swain J, Goldfine AB, et al.: Effects of a low-glycemic load diet on resting energy expenditure and heart disease risk factors during weight loss. JAMA 2004, 292:2482–2490.CrossRefPubMed Pereira MA, Swain J, Goldfine AB, et al.: Effects of a low-glycemic load diet on resting energy expenditure and heart disease risk factors during weight loss. JAMA 2004, 292:2482–2490.CrossRefPubMed
82.
Zurück zum Zitat Rokling-Andersen MH, Reseland JE, Veierød MB, et al.: Effects of long-term exercise and diet intervention on plasma adipokine concentrations. Am J Clin Nutr 2007, 86:1293–1301.PubMed Rokling-Andersen MH, Reseland JE, Veierød MB, et al.: Effects of long-term exercise and diet intervention on plasma adipokine concentrations. Am J Clin Nutr 2007, 86:1293–1301.PubMed
83.
Zurück zum Zitat Olson TP, Dengel DR, Leon AS, Schmitz KH: Changes in inflammatory biomarkers following one-year of moderate resistance training in overweight women. Int J Obes (London) 2007, 31:996–1003.CrossRef Olson TP, Dengel DR, Leon AS, Schmitz KH: Changes in inflammatory biomarkers following one-year of moderate resistance training in overweight women. Int J Obes (London) 2007, 31:996–1003.CrossRef
84.
Zurück zum Zitat Okita K, Nishijima H, Murakami T, et al.: Can exercise training with weight loss lower serum C-reactive protein levels? Arterioscler Thromb Vasc Biol 2004, 24:1868–1873.CrossRefPubMed Okita K, Nishijima H, Murakami T, et al.: Can exercise training with weight loss lower serum C-reactive protein levels? Arterioscler Thromb Vasc Biol 2004, 24:1868–1873.CrossRefPubMed
85.
Zurück zum Zitat Busetto L, Bassetto F, Zocchi M, et al.: The effects of the surgical removal of subcutaneous adipose tissue on energy expenditure and adipocytokine concentrations in obese women. Nutr Metab Cardiovasc Dis 2008, 18:112–120.CrossRefPubMed Busetto L, Bassetto F, Zocchi M, et al.: The effects of the surgical removal of subcutaneous adipose tissue on energy expenditure and adipocytokine concentrations in obese women. Nutr Metab Cardiovasc Dis 2008, 18:112–120.CrossRefPubMed
86.
Zurück zum Zitat Laimer M, Ebenbichler CF, Kaser S, et al.: Markers of chronic inflammation and obesity: a prospective study on the reversibility of this association in middle-aged women undergoing weight loss by surgical intervention. Int J Obes Relat Metab Disord 2002, 26:659–662.CrossRefPubMed Laimer M, Ebenbichler CF, Kaser S, et al.: Markers of chronic inflammation and obesity: a prospective study on the reversibility of this association in middle-aged women undergoing weight loss by surgical intervention. Int J Obes Relat Metab Disord 2002, 26:659–662.CrossRefPubMed
87.
Zurück zum Zitat Vázquez LA, Pazos F, Berrazueta JR, et al.: Effects of changes in body weight and insulin resistance on inflammation and endothelial function in morbid obesity after bariatric surgery. J Clin Endocrinol Metab 2005, 90:316–322.CrossRefPubMed Vázquez LA, Pazos F, Berrazueta JR, et al.: Effects of changes in body weight and insulin resistance on inflammation and endothelial function in morbid obesity after bariatric surgery. J Clin Endocrinol Metab 2005, 90:316–322.CrossRefPubMed
88.
Zurück zum Zitat Gavrila A, Peng CK, Chan JL, et al.: Diurnal and ultradian dynamics of serum adiponectin in healthy men: comparison with leptin, circulating soluble leptin receptor, and cortisol patterns. J Clin Endocrinol Metab 2003, 88:2838–2843.CrossRefPubMed Gavrila A, Peng CK, Chan JL, et al.: Diurnal and ultradian dynamics of serum adiponectin in healthy men: comparison with leptin, circulating soluble leptin receptor, and cortisol patterns. J Clin Endocrinol Metab 2003, 88:2838–2843.CrossRefPubMed
89.
Zurück zum Zitat Kanabrocki EL, Hermida RC, Wright M, et al.: Circadian variation of serum leptin in healthy and diabetic men. Chronobiol Int 2001, 18:273–283.CrossRefPubMed Kanabrocki EL, Hermida RC, Wright M, et al.: Circadian variation of serum leptin in healthy and diabetic men. Chronobiol Int 2001, 18:273–283.CrossRefPubMed
Metadaten
Titel
Inflammation: The Link Between Obesity and Cardiovascular Risk
verfasst von
Paolo Calabrò
Enrica Golia
Lucia Riegler
Giuseppe Limongelli
Paolo Golino
Maria Giovanna Russo
Raffaele Calabrò
Publikationsdatum
01.03.2010
Verlag
Current Science Inc.
Erschienen in
Current Cardiovascular Risk Reports / Ausgabe 2/2010
Print ISSN: 1932-9520
Elektronische ISSN: 1932-9563
DOI
https://doi.org/10.1007/s12170-010-0087-7

Weitere Artikel der Ausgabe 2/2010

Current Cardiovascular Risk Reports 2/2010 Zur Ausgabe

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.